Meo SD - Search Results

1

Hemoproteins affect H(2)O(2) removal from rat tissues.

Venditti P, Masullo P, Meo SD. Venditti P, et al. Among authors: meo sd. Int J Biochem Cell Biol. 2001 Mar;33(3):293-301. doi: 10.1016/s1357-2725(00)00086-8. Int J Biochem Cell Biol. 2001. PMID: 11311861

2

Effect of exercise duration on characteristics of mitochondrial population from rat liver.

Venditti P, Masullo P, Meo SD. Venditti P, et al. Among authors: meo sd. Arch Biochem Biophys. 1999 Aug 1;368(1):112-20. doi: 10.1006/abbi.1999.1269. Arch Biochem Biophys. 1999. PMID: 10415118

3

Electrophysiological properties of the hyperthyroid rat heart.

Meo SD, de Martino Rosaroll P, Piro MC, De Leo T. Meo SD, et al. Arch Int Physiol Biochim Biophys. 1994 Mar-Apr;102(2):153-9. doi: 10.3109/13813459408996124. Arch Int Physiol Biochim Biophys. 1994. PMID: 7519464

4

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

Gion M, Plebani M, Mione R, Penzo C, Meo S, Burlina A. Gion M, et al. Br J Cancer. 1994 Apr;69(4):721-5. doi: 10.1038/bjc.1994.136. Br J Cancer. 1994. PMID: 8142260 Free PMC article.

5

Biochemical parameters for prognostic evaluation in patients with breast cancer.

Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Sampognaro E, Meo S. Gion M, et al. Anticancer Res. 1994 Mar-Apr;14(2B):693-8. Anticancer Res. 1994. PMID: 8010728

6

Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments.

Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, Gion M. Dittadi R, et al. Int J Biol Markers. 2001 Apr-Jun;16(2):87-96. Int J Biol Markers. 2001. PMID: 11471901

7

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.

8

Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.

Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Gatti C, Paccagnella A, Rosabian A, Vinante O, Meo S. Gion M, et al. Breast Cancer Res Treat. 2000 Feb;59(3):211-21. doi: 10.1023/a:1006318112776. Breast Cancer Res Treat. 2000. PMID: 10832591

9

The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.

Meo S, Dittadi R, Peloso L, Gion M. Meo S, et al. Int J Biol Markers. 2004 Oct-Dec;19(4):282-8. doi: 10.1177/172460080401900405. Int J Biol Markers. 2004. PMID: 15646834 Free article.

10

Ca549 immunoassay in breast-tissue - comparison with ca15.3 and mca.

Gion M, Plebani M, Mione R, Capitanio G, Penzo C, Meo S. Gion M, et al. Int J Oncol. 1993 Oct;3(4):695-9. doi: 10.3892/ijo.3.4.695. Int J Oncol. 1993. PMID: 21573420

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page